Bosulif Drug Analysis 2018: A Kinase Inhibitor that Targets the BCR-ABL Kinase and Also Inhibits the SRC-Family Kinases that Include SRC, LYN, and HCK - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Bosulif" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bosulif (bosutinib; Pfizer) is a kinase inhibitor that targets the BCR-ABL kinase and also inhibits the Src-family kinases that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated in the presence of an abnormal BCR-ABL fusion protein, which is a common hallmark of chronic myeloid leukemia (CML). Over expression of specific Src kinases is associated with Gleevec-resistant CML phenotypes. In mice, treatment with Bosulif reduced the size of CML tumors relative to controls and inhibited growth of murine myeloid tumors expressing several Gleevec-resistant forms of BCR-ABL.

Bosulif was the fourth tyrosine kinase inhibitor (TKI) to enter the CML market and is most commonly used in the third-line setting. Bosulif benefits from its activity against CML mutations that confer resistance to Gleevec (imatinib; Novartis), Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka), and Tasigna (nilotinib; Novartis). The drug failed to demonstrate a statistically significant difference in cytogenetic response versus Gleevec in the Phase III BELA trial; however, Pfizer is making a second attempt in first-line CML with the Phase III BFORE trial. Nonetheless, Bosulif's late entry into the CML market will continue to hinder its uptake.

Key Topics Covered:

List of Figures

Figure 1: Bosulif for CML - SWOT analysis
Figure 2: Drug assessment summary of Bosulif for CML
Figure 3: Drug assessment summary of Bosulif for CML

List of Tables

Table 1: Bosulif drug profile
Table 2: Bosulif pivotal trial data in CML
Table 3: Bosulif late-phase trial data in CML

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mcd8bj/bosulif_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs